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Objective: Sleep-disordered breathing (SDB) is a widespread disease that is often
associated with heart failure (HF) with preserved ejection fraction (HFpEF). HFpEF is
more frequent in women than in men, but detailed pathomechanisms remain unclear.
We investigated HFpEF in women and men in a high-risk cohort with SDB monitoring.
Methods and Results: Three hundred twenty-seven patients (84.4% men) undergoing
elective coronary artery bypass grafting were prospectively subjected to SDBmonitoring,
and an apnea–hypopnea index (AHI) ≥15/h defined SDB. HF was classified according to
current guidelines. HFpEF was significantly more frequent in SDB patients compared to
those without SDB (28 vs. 17%, P = 0.016). This distribution was driven by an increased
frequency of HFpEF in female SDB patients (48% vs. only 25% in male, P = 0.022).
In accordance, female patients with SDB exhibited significantly more impaired diastolic
left ventricular filling compared to men (echocardiographic E/e
′
). In contrast to men,
in women, minimum oxygen saturation (O2min, measured by polygraphy, R
2 = 0.470,
P < 0.001) and time of oxygen saturation <90% (R2 = 0.165, P = 0.044) were
significantly correlated with E/e
′
. Moreover, the correlation between O2min and E/e
′
was
significantly different in women compared tomen (P< 0.001). Intriguingly, this association
remained independent of clinical covariates in women [age, body mass index, systolic
contractile dysfunction, diabetesmellitus, and glomerular filtration rate (GFR),R2 = 0.534,
P = 0.042, multivariate regression analysis]. Since angiotensin II signaling has been
mechanistically linked to HF, we measured protein expression of its cleavage enzyme
ACE2 in human right atrial appendage biopsies (Western blot). Intriguingly, we found a
significantly decreased ACE2 expression preferentially in women with SDB (2.66 ± 0.42
vs. 4.01 ± 2.47 in men with SDB, P = 0.005). In accordance, left ventricular mass index
was significantly increased in women with SDB compared to women without SDB.
Conclusion: In patients with SDB, HFpEF and diastolic dysfunction were more frequent
in women compared to men. In contrast to men, the severity of SDB was associated
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with the degree of diastolic dysfunction in women. These insights might help to find
sex-specific therapies for patients with sleep-disordered breathing and heart failure.
Clinical Trial Registration: Unique identifier: NCT02877745, URL: http://www.
clinicaltrials.gov.
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INTRODUCTION
Sleep-disordered breathing (SDB) is a widespread disease with
increasing prevalence and emerging socioeconomic relevance
(1). The major drivers of the increasing prevalence are the aging
population and the ongoing obesity epidemic (2). Unfortunately,
SDB can contribute to hypertension (3) and is often associated
with severe comorbidities that substantially worsen prognosis,
like atrial fibrillation (4) or heart failure (HF) (5, 6). Both SDB and
HF are especially frequent in high-risk patients, e.g., in patients
with acute myocardial infarction (7) or in patients undergoing
coronary artery bypass grafting (CABG) (5–8). In particular, HF-
dependent congestion in the pulmonary circuit with subsequent
pulmonary hypertension may also contribute to increased
SDB severity (9).
HF can be classified into HF with reduced ejection fraction
(HFrEF), mid-range ejection fraction, and preserved ejection
fraction (HFpEF) (6). Interestingly, HFpEF is more frequent in
women, and HFrEF is more likely to be found in men, while
detailed mechanisms remain elusive (6, 10, 11). In addition,
there is only sparse data regarding this important issue in high-
risk patients with SDB. Therefore, there is an urgent need for
further insights regarding SDB and HF in high-risk patients
that may guide us to future therapeutic strategies. HFpEF has
already been shown to be associated with left atrial enlargement
and left ventricular hypertrophy (10, 11). Interestingly, the latter
has been mechanistically linked to an increased angiotensin II
signaling that can be alleviated by angiotensin II cleavage enzyme
angiotensin-converting enzyme 2 (ACE2) (12).
The present study aims to characterize HFpEF and diastolic
dysfunction in women and men with SDB of a high-risk patients’
cohort undergoing CABG.Moreover, wemeasured ACE2 protein
expression in a human myocardium as a potential sex-dependent
pathway that may lead to hypertrophy and subsequent HFpEF.
MATERIALS AND METHODS
This is a cross-sectional experimental and clinical sub-study
of the prospective observational study “Impact of sleep-
disordered breathing on atrial fibrillation and perioperative
complications in patients undergoing coronary artery
bypass grafting surgery—a prospective observational study”
Abbreviations: ACE2, angiotensin-converting enzyme 2; AHI, apnea–hypopnea
index; CABG, coronary artery bypass grafting; HF, heart failure; HIF-1α, hypoxia-
inducible factor 1α; HFpEF, heart failure with preserved ejection fraction; HFrEF,
heart failure with reduced ejection fraction; LVEF, left ventricular ejection fraction;
NT-pro BNP, N-terminal-pro brain natriuretic peptide; O2min, minimum oxygen
saturation; SDB, sleep-disordered breathing.
(CONSIDER-AF: NCT02877745, https://clinicaltrials.gov/ct2/
show/NCT02877745?term=NCT02877745&rank=1) (13).
Study Approval and Design
This study was approved by the local ethics committee
(University of Regensburg, Bavaria, Germany) and is in
accordance with the Declaration of Helsinki (first released in
1964, most recent revision 2013). Between May 2016 and May
2019, each patient that was scheduled for elective CABG at
the University Hospital Regensburg was prospectively screened
for eligibility. Age between 18 and 85 years, planned elective
CABG, and provided written informed consent were inclusion
criteria. Pre-specified exclusion criteria were preexisting treated
SDB, nocturnal positive airway pressure support or mechanical
ventilation, severe obstructive pulmonary disease, oxygen
therapy, and preoperative use of inotropes or intra-aortic balloon
pump. This resulted in 415 patients that were tested as eligible
(Figure 1). Twenty-one patients withdrew their consent, 47
polygraphies were insufficient, 18 surgeries were canceled, and
2 other patients had to be excluded, resulting in a final study
subpopulation of 327 patients from which echocardiographic
data were available. Some patients (N = 99) donated a right
atrial appendage biopsy for further experimental analyses.
For optimal cardioplegia, biopsies were transported to our
laboratories in ice-cold Custodiol R© solution (with 2 mmol/L
butanedione monoxime).
Assessment of SDB
SDB was assessed using standard polygraphy during the night
before surgery (Alice NightOne Device; Philips Respironics,
Murrysville, USA). Airflow, blood oxygen levels, and respiratory
efforts were measured. The acquired sleep data were analyzed by
experienced medical staff using Sleepware G3 sleep diagnostic
software (Philips Respironics, Murrysville, USA). As described
previously, there was a ≥90% decrease in airflow for ≥10 s
defined apneas (8). Hypopneas were defined as ≥30–90%
decrease in airflow vs. baseline for ≥10 s and desaturation as a
≥4% decrease in oxygen saturation (14, 15). An apnea–hypopnea
index (AHI, mean occurrence of apneas and hypopneas/h sleep)
≥15/h defined SDB. Mean number of desaturations/h sleep
defined the oxygen desaturation index (8).
Classification of HF
HF was classified according to current guidelines (6). HFrEF
was defined by having symptoms and a left ventricular ejection
fraction (LVEF) <40%. HF with mid-range ejection fraction was
defined by having symptoms with LVEF 40–49% and elevated N-
terminal-pro brain natriuretic peptide (NT-pro BNP) levels and
Frontiers in Medicine | www.frontiersin.org 2 May 2021 | Volume 8 | Article 675987
Lebek et al. HFpEF in Female SDB Patients
FIGURE 1 | Study flowchart. Study flowchart showing the enrolment of 415
patients undergoing elective coronary artery bypass grafting. After exclusion of
88 patients, 166 patients without SDB and 161 patients with SDB (± right
atrial appendage biopsies) were prospectively analyzed.
either left ventricular hypertrophy (left ventricular mass index
≥115 g/m2 for male, ≥95 g/m2 for female patients), left atrial
enlargement (left atrial volume index >34 ml/m2), or diastolic
dysfunction. HFpEF was defined by having symptoms with LVEF
≥50% and elevated NT-pro BNP levels and either left ventricular
hypertrophy, left atrial enlargement, or diastolic dysfunction.
Western Blots
Human right atrial appendage biopsies were homogenized
using Tris buffer, containing (mmol/L) 20 Tris–HCl, 200
NaCl, 20 NaF, 8.9 Nonidet P-40 (Sigma Aldrich), 18.3
phenylmethanesulfonylfluoride (Sigma Aldrich), complete
protease inhibitor cocktail (Roche), and complete phosphatase
inhibitor cocktail (Roche). Protein concentration was measured
by a bicinchoninic acid (BCA) assay (Pierce Biotechnology).
After denaturation [30min at 37◦C at 500 rpm in 2% β-
mercaptoethanol (Sigma Aldrich)], proteins were separated
on 8% sodium dodecyl sulfate (SDS)–polyacrylamide gels and
transferred to a nitrocellulose membrane (GE Healthcare).
Primary antibodies [rabbit monoclonal anti-ACE2 (1:5000,
Abcam, catalog number ab108252) and mouse monoclonal
antiglyceraldehyde 3-phosphate dehydrogenase (anti-GAPDH)
(1:10,000, Sigma Aldrich, catalog number G8795)] were
incubated at 4◦C overnight. Secondary antibodies [horseradish
peroxidase (HRP)-conjugated sheep antirabbit immunoglobulin
G (IgG) for anti-ACE2 (1:5000, GE Healthcare, catalog number
NA934) and HRP-conjugated sheep antimouse IgG for anti-
GAPDH (1:10,000, GE Healthcare, catalog number NA931VS)]
were incubated at room temperature for 1 h. To facilitate
detection of protein bands, we incubated with ImmobilonTM
Western Chemiluminescent HRP Substrate (Millipore) at room
temperature for 5min. Protein bands were developed onto
Super XR-N X-ray films (Fujifilm), scanned by ChemiDocTM MP
Imaging System (Bio-Rad), and densitometry was performed
using ImageJ.
Statistical Analysis
All experiments were conducted and analyzed by investigators
that were blinded to the clinical data. Categorial and continuous
clinical variables are reported as total number (with relative
proportion) and mean ± standard deviation (SD), respectively.
Experimental data are presented as means ± standard error of
themean (SEM). The average was calculated whenmore than one
measurement of the same kind of experiment could be acquired
in the same patient to obtain one single value for each patient.
Normal distribution was tested using Shapiro–Wilk normality
test in GraphPad Prism 9. If a variable was normally distributed,
significance was tested by a parametric test. Otherwise, the
appropriate non-parametric test was used. For the comparison
of two groups, we used Student’s t and Mann–Whitney tests
as parametric and non-parametric test, respectively. One-way
analysis of variance (ANOVA) with Holm–Sidak’s post hoc
correction was applied for the comparison of more than two
groups that were normally distributed. Kruskal–Wallis test with
Dunn’s post hoc correction was used for the comparison of more
than two groups that were not normally distributed. Chi-square
test was used for the comparison of categorial data.
Univariate linear regression analyses were performed using
IBM SPSS Statistics 25 to test for the following potential
confounders and effect modifiers: age, body mass index, arterial
hypertension, existing HFrEF, existing atrial fibrillation, history
of stroke, diabetes mellitus, and glomerular filtration rate. All
variables with P < 0.3 in the univariate regression analyses were
included in a multivariate model.
To test whether a correlation was significantly different
in women and men, the interaction term was calculated by
multiplying the independent variable with either 0 or 1 for
men and women, respectively. Then, multivariate regression
analysis was performed incorporating the independent variable,
gender, and the interaction term. If the interaction term’s
P < 0.05, the correlation between the independent variable
and the response variable was considered to be significantly
different in women and men. For each regression analysis, the
regression coefficient B with the 95% confidence interval for each
variable was presented. P-values below 0.05 were considered as
statistically significant.
RESULTS
Baseline Characteristics of Study
Population
Three hundred twenty-seven patients undergoing elective CABG
were included in this study. Polygraphy revealed the presence
of moderate to severe SDB (AHI ≥15/h) in 161 patients
(49%, Table 1 and Figure 1). In accordance with previous data,
patients with SDB were older (P = 0.046), had a higher body
mass index (P = 0.006), and a tendency toward increased
prevalence of arterial hypertension (P = 0.053) and atrial
fibrillation (P = 0.080). Accordingly, history of stroke was
significantly more common in patients with SDB (P = 0.003).
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TABLE 1 | Baseline characteristics.
Total cohort (N = 327) No SDB (N = 166) SDB (N = 161) P-value
Age, years, mean ± SD 67.3 ± 8.3 66.4 ± 9.0 68.3 ± 7.5 0.046T
Male gender, N (%) 276 (84.4%) 138 (83.1%) 138 (85.7%) 0.520Chi
Body mass index, kg/m2, mean ± SD 28.7±4.4 28.0±4.0 29.4±4.6 0.006T
Art. Hypertension, N (%) 280 (85.6%) 136 (81.9%) 144 (89.4%) 0.053Chi
Diabetes mellitus, N (%) 110 (33.6%) 52 (31.3%) 58 (36.0%) 0.369Chi
Hyperlipidemia, N (%) 215 (65.7%) 103 (62.0%) 112 (69.6%) 0.152Chi
Atrial fibrillation, N (%) 55 (16.8%) 22 (13.3%) 33 (20.5%) 0.080Chi
History of stroke, N (%) 29 (8.9%) 7 (4.2%) 22 (13.7%) 0.003Chi
Heart function
HF, N (%) 120 (36.7%) 39 (23.5%) 81 (50.3%) <0.001Chi
HFrEF, N (%) 25 (7.6%) 6 (3.6%) 19 (11.8%) 0.005Chi
HFmrEF, N (%) 22 (6.7%) 5 (3.0%) 17 (10.6%) 0.006Chi
HFpEF, N (%) 73 (22.3%) 28 (16.9%) 45 (28.0%) 0.016Chi
NYHA functional class§
Class I, N (%) 9 (2.8%) 4 (2.4%) 5 (3.1%) 0.701Chi
Class II, N (%) 64 (19.6%) 22 (13.3%) 42 (26.1%) 0.003Chi
Class III, N (%) 43 (13.1%) 12 (7.2%) 31 (19.3%) 0.001Chi
Class IV, N (%) 4 (1.2%) 1 (0.6%) 3 (1.9%) 0.300Chi
NT-pro BNP, pg/ml, mean ± SD 1389.9 ± 3963.0 1033.7 ± 4135.3 1748.6 ± 3762.1 <0.001MW
LVEF, %, mean ± SD 56.1 ± 9.7 58.5 ± 7.6 53.6 ± 11.0 <0.001MW
GFR, ml/min, mean ± SD 73.8 ± 21.3 76.2 ± 21.1 71.2 ± 21.4 0.025MW
Angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker, N (%) 245 (74.9%) 124 (74.7%) 121 (75.2%) 0.924Chi
Values are either the number of patients (relative percentage in parenthesis) or mean ± SD, as appropriate. Comparisons shown in bold values are statistically significant.
§ If HF was diagnosed.
Chi, chi-square test; GFR, glomerular filtration rate; HF, heart failure; HFmrEF, heart failure with mid-range ejection fraction; LVEF, left ventricular ejection fraction; MW, Mann–Whitney
test; NYHA, New York Heart Association; SD, standard deviation; T, Student’s t-test.
Importantly, patients with SDB were more likely to present
with HF (81/161 vs. 39/166, P < 0.001). In accordance, New
York Heart Association (NYHA) functional class and levels
of NT-pro BNP (P < 0.001) were also significantly increased.
Patients with SDB exhibited a significantly reduced LVEF (P
< 0.001) and an impaired renal function (glomerular filtration
rate, P = 0.025). By definition, patients with SDB showed a
significantly increased oxygen desaturation index (/h, 28.2 ±
15.5 vs. 6.6 ± 4.3, P < 0.001) and decreased minimum oxygen
saturation (O2min in %, 78.3 ± 7.0 vs. 82.5 ± 6.0, P < 0.001),
indicating intermittent hypoxemia (Table 2). In patients with
SDB, central apnea index (12.5 ± 13.4, P < 0.001 vs. no SDB)
was higher than the obstructive apnea index (9.7 ± 11.0, P <
0.001 vs. no SDB), without statistical difference between the
frequency of the abnormal breathing types (P = 0.398). Female
patients with SDB were significantly older (P= 0.022) with more
severe HF symptoms (NYHA functional class) (Table 3) than
male patients with SDB. On the other hand, there was no sex-
dependent age difference for the total cohort (female vs. male,
68.1 ± 9.2 vs. 67.2 ± 8.2 years, N = 51 vs. 276, P = 0.448,
Student’s t-test). In patients with HF, those with HFpEF exhibited
increased obstructive (6.8 ± 8.0 vs. 5.5 ± 8.9, P = 0.044) and
central apnea indices (10.1 ± 14.3 vs. 6.2 ± 9.6, P = 0.083)
compared to patients without HFpEF. However, obstructive and
central apnea indices were not significantly different, neither
in patients without HFpEF (P = 0.245) nor in those with
HFpEF (P = 0.864).
Female SDB Patients Exhibit HFpEF More
Frequently
As reported in Table 1, HFpEF was significantly more frequent
in SDB patients (48/161 vs. 28/166, P = 0.016). Intriguingly,
this distribution was mainly driven by an increased frequency of
HFpEF in female SDB patients (11/23 vs. only 34/138 in male, P
= 0.022, Figure 2A). Compared to female patients without SDB,
women with SDB exhibited significantly increased levels of NT-
pro BNP (P = 0.048, Figure 3A). In accordance with increased
prevalence of HFpEF, there was a significantly increased ratio of
transmitral early peak velocity and early diastolic mitral annulus
velocity (E/e
′
) of 17.0± 8.5 in womenwith SDB compared to 11.2
± 3.9 in women without SDB (P = 0.009) and compared to 12.4
± 5.0 in male SDB patients (P = 0.009, Figure 2B). Consistent
with a gender-based difference in diastolic dysfunction in SDB,
there was significant negative correlation of E/e
′
with O2min only
in women (R2 = 0.470, P < 0.001, Figure 2C) but not in men
(R² < 0.001, P = 0.762, Figure 2C). Moreover, this association
was significantly different and stronger in women than in men (P
< 0.001, Table 5). Similarly, E/e
′
was also significantly positively
correlated with the duration of oxygen saturation below 90% (R2
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TABLE 2 | Polygraphy data.
Total cohort (N = 327) No SDB (N = 166) SDB (N = 161) P-value
Total recording time, min 473.5 ± 59.9 475.3 ± 60.4 471.5 ± 59.5 0.210MW
Apnea-hypopnea index, /h 19.7 ± 16.2 7.8 ± 4.1 32.0 ± 14.7 <0.001MW
Obstructive apnea index, /h 5.8 ± 8.7 2.1 ± 2.2 9.7 ± 11.0 <0.001MW
Central apnea index, /h 7.1 ± 10.9 (P = 0.250MW
vs. obstructive apnea index)
1.9 ± 2.2 (P = 0.045MW vs.
obstructive apnea index)
12.5 ± 13.4 (P = 0.398MW
vs. obstructive apnea index)
<0.001MW
Oxygen desaturation index, /h 17.2 ± 15.6 6.6 ± 4.3 28.2 ± 15.5 <0.001MW
Minimum oxygen saturation, % 80.4 ± 6.8 82.5 ± 6.0 78.3 ± 7.0 <0.001MW
Mean oxygen saturation, % 91.7 ± 2.3 92.1 ± 2.0 91.3 ± 2.4 <0.001MW
Mean heart rate, /min 72.2 ± 12.3 71.7 ± 12.3 72.6 ± 12.4 0.480MW
All values are presented as mean ± standard deviation, and comparisons shown in bold values are statistically significant. An apnea–hypopnea index ≥15/h defined sleep-disordered
breathing (SDB).
MW, Mann–Whitney test; TRT, total recording time.
TABLE 3 | Baseline characteristics of women and men with SDB.
Female (N = 23) Male (N = 138) P-value
Age, years, mean ± SD 71.6 ± 8.1 67.7 ± 7.3 0.022T
Body mass index, kg/m2, mean ± SD 29.8 ± 4.6 29.3 ± 4.6 0.637T
Art. Hypertension, N (%) 21 (91.3%) 123 (89.1%) 0.753Chi
Diabetes mellitus, N (%) 8 (34.8%) 50 (36.2%) 0.893Chi
Hyperlipidemia, N (%) 14 (60.9%) 98 (71.0%) 0.328Chi
Atrial fibrillation, N (%) 6 (26.1%) 27 (19.6%) 0.473Chi
History of stroke, N (%) 4 (17.4%) 18 (13.0%) 0.574Chi
Heart function
HF, N (%) 12 (52.2%) 69 (50.0%) 0.847Chi
NYHA functional class§
Class I, N (%) 0 (0.0%) 5 (3.6%) 0.354Chi
Class II, N (%) 4 (17.4%) 38 (27.5%) 0.305Chi
Class III, N (%) 8 (34.8%) 23 (16.7%) 0.041Chi
Class IV, N (%) 0 (0.0%) 3 (2.2%) 0.475Chi
Apnea–hypopnea index, /h, mean ± SD 32.8 ± 20.3 31.8 ± 13.6 0.349MW
Minimum oxygen saturation, %, mean ± SD 77.5 ± 6.1 78.4 ± 7.1 0.342MW
GFR, ml/min, mean ± SD 64.2 ± 23.1 72.4 ± 21.0 0.093MW
Values are either the number of patients (relative percentage in parenthesis) or mean ± SD, as appropriate. Comparisons shown in bold values are statistically significant.
§ If heart failure was diagnosed.
Chi, chi-square test; GFR, glomerular filtration rate; HF, heart failure; MW, Mann–Whitney test; NYHA, New York Heart Association; SD, standard deviation; T, Student’s t-test.
= 0.165, P=0.044) only in female but not in male patients. Other
parameters of diastolic dysfunction were altered in a similar
direction: compared to male, female SDB patients exhibited
significantly decreased e
′
(P = 0.027, Figure 3B).
As indicated in Table 1, patients are heterogeneous and
present with several comorbidities that could potentially
confound our data. Based on these differences, we conducted
univariate regression analyses for E/e
′
and minimum oxygen
saturation (O2min), as measure of hypoxia during SDB, age,
body mass index, arterial hypertension, existing HFrEF, existing
atrial fibrillation, history of stroke, diabetes mellitus, and
glomerular filtration rate for all female patients (Table 4).
Besides O2min, age, glomerular filtration rate, and HFrEF
by trend predicted the severity of diastolic dysfunction in
women. Female SDB patients were older than female patients
without SDB (71.6 ± 8.1 vs. 65.3 ± 9.3 years, N = 23 vs.
28, P = 0.015). The different age distribution may result
in confounding. Therefore, we incorporated age and other
important comorbidities into multivariate linear regression
analysis. Importantly, after inclusion of all variables with P < 0.3
into a multivariate regression model, O2min remained the only
independent predictor for the severity of diastolic dysfunction in
women (R2 = 0.534, P = 0.042, Table 4).
Structural Remodeling in Women With SDB
Since HFpEF is also defined by atrial enlargement and
hypertrophy, we analyzed these parameters in our patient cohort.
Interestingly, in female SDB patients, left atrial volume index was
increased by trend (Figure 3D), and left atrial area index was
significantly increased compared to womenwithout SDB. The left
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FIGURE 2 | Increased frequency of HFpEF in women with SDB. (A) Proportion of patients having heart failure with preserved ejection fraction (HFpEF). Interestingly,
HFpEF was significantly more common in women with SDB (N = 11/23) compared to men with SDB (N = 34/138). (B) Accordingly, the severity of diastolic
dysfunction, estimated by E/e
′
, was significantly increased in women with SDB (N = 9) compared to women without SDB (N = 16) and men with SDB (N = 50). (C)
This resulted in significant correlations between E/e
′
with both O2min and time of oxygen saturation <90% (% of total recording time) in women but not in men,
indicating that hypoxia may be involved in HFpEF-development in women. (D) Original Western blots for the analysis of ACE2 expression in right atrial appendage
biopsies. (E) Intriguingly, densiometric analyses revealed that ACE2 expression was significantly decreased in women with SDB (N = 4), leading to a significant
correlation with O2min in women (N = 10) but not in men (N = 82). Statistical comparisons are based on (A) chi-square test (B,E), one-way analysis of variance
(ANOVA), and (C,E) linear regression analysis.
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FIGURE 3 | Diastolic dysfunction in women with SDB. (A) In accordance with an increased frequency of heart failure in women and men with SDB (Table 1), we
observed a significantly increased level of NT-pro BNP in women (N = 19 vs. N = 27) and men (N = 126 vs. N = 119) with SDB. (B) Early diastolic mitral annulus
velocity (e
′
) was significantly decreased in women with SDB (N = 8), indicating diastolic dysfunction. (C) Moreover, left atrial area index was significantly increased in
women with SDB (N = 14) compared to women without SDB (N = 15), leading to a significant correlation with O2min in women but not in men. (D) Consistently, we
observed a trend toward an increased left atrial volume index in women with SDB (N = 4 vs. N = 6). Statistical comparisons are based on (A,B) Kruskal–Wallis test
(C,D) one-way analysis of variance (ANOVA), and (C) linear regression analysis.
atrial area index (cm2/m2) increased from 10.7 ± 1.6 to 13.1 ±
3.7 (P= 0.021, Figure 3C). The latter also correlated significantly
with O2min in female patients R
2 = 0.363, P < 0.001 but not
in male patients (Figure 3C). This suggests that hypoxia may be
mechanistically linked to HFpEF development and subsequent
structural atrial remodeling in women.
Beside atrial dilation, left ventricular hypertrophy is also a
characteristic for HFpEF. Indeed, we observed a significantly
increased left ventricular mass index in women with SDB
compared to women without SDB (P = 0.025, Figure 4A).
Moreover, female SDB patients exhibited a significantly increased
QRS width. Compared to female patients without SDB, QRS
width (in ms) increased from 94.9 ± 21.3 to 113.7 ± 26.7
in women with SDB (P = 0.027, Figure 4B). Consistently, the
magnitude of QRS width was significantly negatively correlated
with O2min in women (R
2 = 0.152, P= 0.012, Figure 4C) but not
in men.
Since angiotensin II signaling is a hallmark for HF and
myocardial hypertrophy, we measured protein expression of its
cleavage enzyme ACE2 in human right atrial appendage biopsies
(Western blots, Figure 2D). Intriguingly, for the cohort of
patients with SDB, ACE2 expression was significantly decreased
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TABLE 4 | O2min independently predicts the severity of diastolic dysfunction in women.
N = 25 Univariate linear regression analyses Multivariate linear regression analysis Adj. R2 = 0.534
Variable: E/e′ B (95% CI) P-value B (95% CI) P-value
O2min (%) −0.569 (−0.830; −0.308) <0.001 −0.333 (−0.652; −0.014) 0.042
Age (years) 0.332 (0.082; 0.582) 0.011 0.233 (−0.031; 0.497) 0.080
Body mass index (kg/m²) 0.346 (−0.206; 0.898) 0.208 0.268 (−0.175; 0.711) 0.219
Arterial hypertension −3.457 (−10.736; 3.821) 0.336
Existing HFrEF 12.192 (−0.675; 25.058) 0.062 4.640 (−6.700; 15.980) 0.401
Existing atrial fibrillation 3.606 (−3.659; 10.871) 0.315
History of stroke −2.049 (−9.426; 5.328) 0.571
Diabetes mellitus 2.799 (−2.553; 8.152) 0.291 2.965 (−0.956; 6.886) 0.130
Glomerular filtration rate (ml/min/1.73 m2) −0.107 (−0.197; −0.017) 0.021 −0.022 (−0.114; 0.070) 0.616
Multivariate linear regression analysis revealed minimum oxygen saturation (O2min ) as an independent predictor for the severity of diastolic dysfunction (i.e., E/e
′
) in women. P-values
shown in bold are statistically significant.
in women (to 2.7± 0.2) compared to men (4.0± 0.4, P= 0.005),
and there was a strong trend compared to women without SDB
(5.3 ± 1.4, P = 0.063, Figure 2E). Consistent with a potential
mechanistic role of hypoxia, O2min was significantly positively
correlated with ACE2 expression but only in women (R2 = 0.534,
P = 0.016) and not in men (Figure 2E).
DISCUSSION
In this study, we characterized HF in high-risk patients with
SDB monitoring prior to CABG surgery. While patients with
SDB were at increased risk for HF, in general, women with SDB
were more likely to present with HFpEF compared to men with
SDB. Accordingly, we observed increased cardiac hypertrophy
(left ventricular mass index) in women with SDB, possibly
due to a decreased myocardial ACE2 expression in female
SDB patients.
Increased Frequency of HFpEF in Women
With SDB
Over the last decades, the incidence and prevalence of HF
has increased (6, 11). According to the Framingham Heart
Study, the overall lifetime risk for developing HF was similar
for women and men (16). Despite increasing socioeconomic
importance, therapeutic strategies for patients with HFpEF are
still limited (6). Most recently, in the PARAGON-HF trial,
angiotensin receptor–neprilysin inhibitor sacubitril-valsartan
was tested in patients with HFpEF, but treatment failed to reduce
the combined endpoint of HF hospitalization and death from
cardiovascular causes (17). Therefore, improved understanding
of pathomechanisms may favor better characterization and
phenotyping of patients with HFpEF, which is essential
to find better, personalized HFpEF therapy. Intriguingly,
subgroup analyses of PARAGON-HF trial revealed that in
patients with HFpEF treatment with sacubitril-valsartan, reduced
hospitalization was only observed in women but not in men (18).
Indeed, there are remarkable sex differences when considering
the entities of HF. Overall, HFpEF has been shown to be more
FIGURE 4 | Cardiac remodeling in patients with SDB. (A) Left ventricular mass
index was significantly increased in women with SDB (N = 8) compared to
women without SDB (N = 17). (B) Accordingly, we observed a significantly
increased QRS width in women with SDB (N = 18) and a significant correlation
with O2min in women (N = 41) (C), proposing that hypoxemia may be especially
relevant for myocardial hypertrophy in women. Statistical comparisons are
based on (A,B) Kruskal–Wallis test, and (C) linear regression analysis.
frequent in women than in men (11). However, recent studies
have shown that younger HFpEF patients are more likely obese
non-white men, while older HFpEF patients are predominantly
hypertensive women (19, 20). The different distribution of HF
entities across men and women are even more pronounced in
older patients (21).
Interestingly, we observed increased frequencies of all HF
entities in patients with SDB (Table 1). In addition, LVEF was
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TABLE 5 | The association of O2min and the severity of diastolic dysfunction is different in women and men.
N = 131 Univariate linear regression analyses Multivariate linear regression analysis Adj. R2 = 0.152
Variable: E/e′ B (95% CI) P-value B (95% CI) P-value
O2min (%) −0.133 (−0.253; −0.013) 0.030 −0.019 (−0.146; 0.107) 0.764
Gender 2.112 (−0.070; 4.294) 0.058 46.905 (24.755; 69.056) <0.001
Interaction term 0.020 (−0.007; 0.046) 0.151 −0.550 (−0.822; −0.279) <0.001
The interaction term was calculated by multiplying minimum oxygen saturation (O2min ) with either 1 or 0 for women and men, respectively. Multivariate linear regression analysis revealed
a significant correlation between the interaction term and E/e
′
, indicating that the association of O2min and the severity of diastolic dysfunction (i.e., E/e
′
) was significantly different in
women and men. P-values shown in bold are statistically significant.
reduced in patients with SDB, which is in accordance with
recently published data (22, 23). While the increased risk for
developing HFpEF has been established for female sex and
SDB separately (23), currently only sparse data were published
reporting sex differences for HFpEF in patients with SDB. SDB
is a widespread disease affecting almost one billion people
worldwide (1). Interestingly, analyses of 12,608,637 patients
from the National Inpatient Sample revealed that 3.8% of
patients with obstructive sleep apnea (mean age, 62.5 years) were
discharged with HFpEF (23). On the other hand, the prevalence
of obstructive sleep apnea was 16.8% in patients with HFpEF
and only 5.0% in patients without (23). Importantly, we report
here in high-risk patients with severe coronary artery heart
disease undergoing CABG a more than 7-fold increased risk
for HFpEF with 28% in patients with SDB (Table 1). The risk
for HFpEF increases further in women with SDB, showing an
HFpEF frequency of 48%. This is in accordance with the study
of Hwang et al., where 68% of patients hospitalized due to
HFpEF also displayed coronary artery disease, of which 80%
underwent revascularization (63% percutaneous intervention
and 37% CABG) (24).
Potential Mechanisms for HFpEF
Development in Women With SDB
Until now, several mechanisms have already been proposed
to be involved in HFpEF development with secondary atrial
remodeling, e.g., ventricular hypertrophy, arrhythmias, fibrosis,
and inflammatory processes (10, 25, 26). Here, we show
increased left ventricular hypertrophy (Figure 4A) and dilated
atria (Figures 3C,D) in womenwith SDB.Moreover, we observed
an increased QRS width in female SDB patients (Figure 4B), a
feature consistent with ventricular hypertrophy (27).
Interestingly, angiotensin II signaling has been linked to
structural myocardial remodeling (e.g., fibrosis or hypertrophy)
and inflammation (12, 28). In contrast, the latter has been shown
to be inhibited by ACE2-mediated degradation of angiotensin
I to angiotensin (1–9) and angiotensin II to angiotensin (1–
7, 12). In accordance with increased myocardial remodeling, we
could show that the protective ACE2 expression was decreased in
myocardium of womenwith SDB (Figure 2E). The importance of
sex for the regulation of ACE2 expression was confirmed in two
independent cohorts of HF patients. Sama et al. found increased
plasma levels of ACE2 in male compared to female patients
with HF (29).
Several mechanisms of regulation of ACE2 expression have
been proposed. Among them, hypoxia, which activates hypoxia-
inducible factor 1α (HIF-1α), has already been shown to decrease
ACE2 expression possibly by ADAM17-dependent proteolysis
and ectodermal shedding of ACE2 (12, 30, 31). On the other
hand, our group has recently demonstrated that treatment with
either angiotensin-converting enzyme inhibitor or angiotensin
II receptor blocker was associated with an increased myocardial
ACE2 expression (32). Although 245 (74.9%) of our study
patients received either drug, the treatment frequency was similar
in patients without (74.7%) and with SDB (75.2%, P = 0.924,
Table 1), which renders it unlikely to confound our observations.
Interestingly, we show here that myocardial ACE2 expression
and severity of diastolic dysfunction (E/e
′
) correlated with the
minimum oxygen saturation O2min only in women but not in
men. Moreover, the association between O2min and the severity
of diastolic dysfunction was significantly stronger in women
compared to men (Table 5). Importantly, after inclusion of
all potential confounders in a multivariate regression model,
O2min remained the only independent predictor for diastolic
dysfunction in women.
In accordance with our finding, expression of HIF-1α has
been reported to be increased in female but not in male
rat hearts following coronary ligation. This sex difference was
observed despite a comparable amount of hypoxia, suggesting
that the hypoxia-dependent increase in HIF-1α expression may
be larger in female compared to male myocardium (33). In
fact, HIF-1α gene has been shown to bear an estrogen response
element, and HIF-1α expression was increased by estrogen
receptor-α signaling (34).
In contrast, testosterone has been suggested to alleviate
cardiac fibrosis by increased ACE2 activity (35–37).
Postmenopausal women exhibit testosterone levels orders
of magnitude smaller compared to men of comparable age (38).
The role of testosterone for the regulation of ACE2 expression
was corroborated by a study of (Dalpiaz et al.). They reported
a significantly increased myocardial ACE2 activity in male
compared to female spontaneously hypertensive rats, which was
markedly decreased after gonadectomy in males (37).
Thus, increased estrogen but decreased testosterone levels
may predispose women for decreases ACE2 expression in SDB.
Limitations
Since patients with coronary heart disease and HF are typically
more frequently male than female (11), the lower frequency of
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female patients cannot be avoided in our study design. We have
screened every patient, who was scheduled for elective CABG,
for eligibility resulting in 15.6% female patients in this study.
For such a cohort, a similar fraction of female patients has been
reported before (39). Due to variability of anatomy and surgical
techniques, right atrial appendage biopsies are often too small
to perform experimental analyses. Therefore, we were only able
to analyze the right atrium of 10 female (4 with SDB) and
82 male patients (40 with SDB). This represents a fraction of
92/327 patients (28.1%), which is in accordance with previously
published studies using this protocol (8). It should be noted that,
for this technically demanding analysis, a number of four per
group can be frequently found in experimental Western blot
studies. Nevertheless, we cannot exclude error in the statistical
comparison due to less robustness against outliers, and future
studies are needed to confirm our observations.
CONCLUSIONS
In this study, we found amarkedly increased frequency of HFpEF
in women compared to men with SDB in a high-risk cohort of
patients undergoing CABG. Women are often underrepresented
in current HF guidelines, and recent trials with HFpEF patients
were negative but suggest a potential sex difference. Thus, a better
understanding of gender-dependent mechanisms of diastolic
dysfunction is urgently warranted. We suggest that there may be
a gender difference with respect to myocardial ACE2 expression
in response to SDB-dependent hypoxia, favoring hypertrophy
and subsequent HFpEF development in women. However, future
studies are needed to further delineate these pathomechanisms
in detail. Indeed, there are already similar large trials about this
topic ongoing, like SDB-CABG-BO1 (DRKS00014665) (40).
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